Auxly’s Subsidiary Dosecann Enters into Manufacturing and Distribution Agreement with dosist™, an Award-Winning Wellness Company

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis products market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with GSW Creative Corporation Canada Inc., doing business as dosist (“dosist”), to manufacture their proprietary wellness vape devices at Dosecann’s facility in Prince Edward Island.

Dosecann will utilize its production capabilities, capacity, and world-class expertise in cannabis derivative products to manufacture dosist’s innovative dose control solutions. dosist will also utilize Auxly’s well-established national distribution channels to bring its proprietary new innovations to Canadians nation-wide, including their newly engineered dose pen 100, their new range of high potency formulas for THC-forward experiences called thc-plus, and their new rechargeable dose pen system. To view the full press release, link here.

Posted in Clients, News

SP Nutraceuticals Launches First Avocado-based Supplement Metavo to Target Insulin Resistance, Support Healthy Metabolism

Metavo contains AvoB, a powerful bioactive discovered by Canadian scientists and  known to support healthy metabolism, blood sugar levels and weight in adults

SP Nutraceuticals (SP), as part of its mission to build healthy communities through plant-based nutrition backed by rigorous science, is proud to announce the launch of Metavo, a natural supplement that contains avocatin B (AvoB). AvoB is a powerful bioactive naturally found in avocados that helps maintain normal blood glucose (sugar) levels and supports healthy metabolism.

In collaboration with a team of nutritional scientists from the University of Guelph lead by renowned nutraceutical expert and researcher, Dr. Paul Spagnuolo, conducted extensive research and identified and isolated the new bioactive. AvoB can be used to maintain a healthy metabolism, blood sugar levels and weight in adults naturally, effectively and safely. It is particularly beneficial for those who are looking to manage blood sugar levels, those who are pre-diabetic, obese or overweight.

Continue reading

Posted in Clients, News

Join us in welcoming Robin Muzzerall, Facility Manager, CAT Victoria-PEI Plant

Robin Muzzerall, Facility Manager, CATC Victoria-Prince Edward Island Plant

The Emergence community welcomes Robin Muzzerall as she begins her new role as Facility Manager at the CAT Victoria-PEI Plant. As Facility Manager, Robin will oversee operations of the newly acquired facility in Victoria by the Sea. The recent acquisition of the 46,000 sq ft campus, which houses both aquatic and dry lab space, will triple the Canadian footprint for the Center for Aquaculture Technologies (CAT) and make it the largest aquaculture CRO in the world with BSL3 containment certification. Robin brings extensive skills to the position with more than 25 years of leadership experience in the Canadian Aquaculture Industry.  She will play a critical role in helping CAT scale its service-orientated activities and further enhance its global reputation while championing innovation within Aquaculture and Bioscience related industries. After sharing her passion for aquaculture across the country, she is thrilled to return home to the Maritimes to establish strong ties with the local community of Victoria and join the thriving bioscience sector on beautiful Prince Edward Island.

Robin’s bio:

Robin was introduced to the culture of lobster while completing her BSc. Biology at St. Mary’s University in Halifax. Following graduation, having an interest in growing livestock, Robin began her aquaculture career on the east coast. Early on this included supervising the wet lab and managing trials for Aqua Health Ltd., in PEI. Following that time Robin has spent more than 25 years as a hands-on manager in freshwater production of salmon and arctic char including responsibilities of broodstock management, egg, fry and smolt production for internal and external customers. She has worked on both coasts and in the north. Robin has also been an integral part of several facility projects including retrofits, new builds and commissioning of new systems.

Robin’s management experience and style is one that encourages growth and development of the skills of others to promote the success of the operation. Robin also sees the value of community engagement to promote the industry.

Robin returned to PEI to join CATC in May 2020, almost full circle to where she began her interest and career in aquaculture.

Connect with Robin on LinkedIN: https://www.linkedin.com/in/robin-muzzerall-20337343/

Follow news from Center for Aquaculture Technologies on LinkedIN: https://www.linkedin.com/company/center-for-aquaculture-technologies/

Related story:

CATC acquires research facility

Posted in Careers, Clients, Leaders

Alpha Cognition Inc. announces granted EU patents and orphan drug designation for its Progranulin platform

Emergence client Alpha Cognition Inc. (ACI) [formerly Neurodyn Cognition], a clinical stage biotherapeutics company, announced today it has been granted two EU patents (EP2249861A1 and EP3009143A1) relating to the treatment of neurodegenerative diseases using progranulin.  Additionally, the FDA, has granted ACI Orphan Drug Designation for its progranulin product platform for the treatment of amyotrophic lateral sclerosis (ALS). Alpha Cognition operates its laboratory facilities in the Prince Edward Island Bioscience Cluster, Canada.

Alpha-602, progranulin, is a protein that has a potent ability to protect neurons that are under stress. In pre-clinical studies, ACI has demonstrated that progranulin can correct the cellular defects caused by the altered patterns of proteins in motor neurons.  ACI is developing a specific form of progranulin, called Alpha-602, for the treatment of ALS patients.

ACI’s growing list of granted patents now includes two more in Europe.  These patents relate to methods and compositions for the treatment of neurodegenerative diseases using progranulin, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression.

The Orphan Drug Act (ODA) provides special incentives for the development of treatments for rare diseases, such as ALS. For a drug to qualify for orphan-drug designation both the drug and the disease must meet certain specified criteria.  In Q1 of 2020, the FDA granted orphan-drug designation to Alpha-602 for the treatment of ALS.  Alpha-602, is currently advancing through pre-clinical development and toxicology programs.

ACI’s Chief Scientific Officer, Dr. Denis Kay, stated, “These granted patents, together with the orphan-drug designation, mark significant milestones in the clinical development path of Alpha-602 for the treatment of ALS.”

For additional information about the Company and its research programs, visit the Company’s website at http://www.alphacognition.com. 

About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

  • Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.
  • Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses to disease. Its use in the treatment of ALS has been patented by ACI.

For additional information about this press release contact:  rcarpenter@alphacognition.com

For additional information about the company contact:  info@alphacognition.com

Or write to:

Investor Relations
Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6

Posted in Clients

Alpha Cognition Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer’s Therapy

April 30, 2020– [Emergence Client] Alpha Cognition Inc. (ACI) [formerly Neurodyn Cognition] today announced that in a pre-Investigational New Drug (Pre-IND) meeting, the U.S. Food and Drug Administration (USFDA) agreed upon a clinical and regulatory pathway for the approval of Alpha-1062, a patented new chemical entity, to treat Alzheimer’s disease.  The FDA has suggested that a single pivotal trial, scheduled for mid 2021, may be sufficient to obtain marketing approval.  ACI also met with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) earlier this year, who also agreed to consider a similar pathway for approval in Japan.

This follows an earlier press release announcing ACI’s partnership with Linical, a Japanese based contract research organization who will provide regulatory consulting and strategic development services, including post-marketing studies, for Alpha-1062 in Japan.

ACI’s Director of Regulatory Affairs, Mrs.Colleen Johns, commented that, “We are pleased with the responses we received from the FDA and the PMDA” She went on to say, “With the confirmation from the FDA that our suggested pathway is acceptable, we are well-positioned to progress the program quickly and efficiently to approval.”

Alpha-1062 is being developed in both an oral tablet and nasal spray format. Clinical trials have demonstrated that, the intranasal formulation showed a decrease of over 90% in GI related adverse events compared to an approved AChEI (Razadyne®) at similar dose levels.

For additional information about the Company and its research programs, visit the Company’s website at http://www.alphacognition.com.

About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

  • Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which may have a positive effect on the disease.
  • Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses. Its use in the treatment of ALS has been patented by ACI and is being investigated in preclinical models.

For additional information about this press release contact:  rcarpenter@alphacognition.com

For additional information about the company contact:  info@alphacognition.com

Or write to: Investor Relations

Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6

Posted in Clients, News

Auxly’s Subsidiary Dosecann Signs Key Supplier Agreement With Medical Cannabis by Shoppers

Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”), a subsidiary of Shoppers Drug Mart Inc., to become a supplier of cannabis products through its online platform. The agreement will see Auxly’s suite of products and brands, including chewables, chocolates, vapes and oil in a bottle, all developed and manufactured at Dosecann, available to consumers across Canada. Dosecann has completed its initial shipment of cannabis products to Shoppers.

“Having our diverse cannabis product offering with Shoppers allows us to reach a wide group of patients across the country with our quality, science-backed products,” said Hugo Alves, CEO of Auxly. “We are proud to partner with Shoppers and look forward to bringing their customers our products, built on Dosecann’s pillars of quality, safety and efficacy.”

Greg Boone, CEO of Dosecann, added: “Our team at Dosecann prides itself on manufacturing products backed by science and advanced research and development to ensure that consumers get the high-quality cannabis products that they need. We think this achievement is a testament to the extraordinary team that we’ve assembled and the rigor and precision that we apply to product development and manufacturing.”

The agreement is for a three-year term, subject to renewal for an additional two years.

About Dosecann LD Inc. Dosecann, a wholly-owned subsidiary of Auxly, is a Canadian developer and manufacturer of innovative cannabis products for the wellness-focused consumer. Dosecann is committed to providing Canadians with quality products designed for everyday use, backed by science and advanced research. Dosecann’s 52,000 square foot, GMP-compliant facility located in Charlottetown, Prince Edward Island, houses extraction, research and development, product formulation, analytical testing and commercial manufacturing for Auxly’s branded cannabis products. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science™.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Email: press@auxly.com

Posted in Cannabis, Clients

Auxly Acquires Exclusive Global Rights to Omega-Rich Ahiflower® Seed Oil for Use in Cannabis Products

Two Emergence clients: Dosecann and Nature’s Crops

Dosecann facility in Prince Edward Island

Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Natures Crops International (“Natures Crops”), a vertically integrated grower and manufacturer of plant-based specialty oils, pursuant to which the Company will purchase the exclusive global rights to Ahiflower® oil for use in Auxly’s diverse portfolio of cannabis products. This multi-year deal will provide Auxly with a proprietary ingredient for use in its current portfolio of cannabis products and the development of next generation cannabis health products that Auxly will commercialize when legally permitted.

“Auxly is committed to bringing innovative and differentiated cannabis products to consumers and this agreement provides our incredible team of scientists with a vegan, complete and balanced omega-rich proprietary ingredient with which to develop exciting products specifically targeted for the wellness consumer segment,” said Hugo Alves, Chief Executive Officer, Auxly.

Nature’s Crops AHIFLOWER® Seed Oil

Ahiflower starts as a non-GMO oilseed crop grown exclusively in the United Kingdom by Natures Crops. After harvesting the Ahiflower seeds, they are cold pressed to produce a crude oil that is exported to Canada where it is further refined into Ahiflower oil at the Natures Crops facility in Kensington, PEI. Ahiflower is a sustainable and traceable vegan polyunsaturated omega 3-6-9 oil, providing an ecologically-sound alternative to fish oils – each acre of Ahiflower produces as much omega-rich oil as 320,000 anchovies. Ahiflower oil contains more combined omegas than other natural plant or seed oils and contains a combination of the elements found in fish, evening primrose, olive, and flax seed oils. “Consumers seeking the utmost in excellence, freshness and traceability in Canadian, science-backed cannabis solutions will find Dosecann’s products compelling,” said Greg Cumberford, VP Science & Regulatory, Natures Crops.

Bob Chapman, Chief Science Officer at Dosecann, added: “Ahiflower oil provides a rich spectrum of naturally occurring omega 3-6-9 fatty acids to complement our cannabinoids, and we look forward to collaborating with the talented team at Natures Crops on research and development for novel cannabis-based solutions to meet consumers’ wellness needs.”

Ahiflower oil is a proprietary, licensed ingredient. In Canada, Ahiflower oil is a registered natural health product and non-GMO certified. It has been approved as a novel food in the European Union and has cleared FDA review status without objection in the United States.

About Natures Crops International

A manufacturer of specialty oils for dietary supplements, nutraceuticals, food, and personal care products, Natures Crops produces oils from the highest quality crops, produced by growers who follow strict management protocols for sustainability and identity preservation. Natures Crops ensures the crops produced are grown, processed, packaged, and delivered in a safe, sustainable, traceable, and cost-competitive manner. The company has operations in Prince Edward Island, Canada and the United Kingdom, with headquarters in North Carolina. Natures Crops is a member of the Council for Responsible Nutrition (CRN). For more information please write to info@naturescrops.com

About Dosecann LD Inc.

Dosecann, a wholly owned subsidiary of Auxly, is a Canadian developer and manufacturer of innovative cannabis products for the wellness-focused consumer. Dosecann is committed to providing Canadians with quality products designed for everyday use, backed by science and advanced research. Dosecann’s 52,000 square foot, GMP-compliant facility located in Charlottetown, Prince Edward Island, houses extraction, research and development, product formulation, analytical testing and commercial manufacturing for Auxly’s branded cannabis products. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science™.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)

Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:
Email: press@auxly.com

Posted in Cannabis, Clients

How one P.E.I. company is using chickens to try to detect COVID-19 in humans

Reprinted from CBC Prince Edward Island. The story was also featured on CBC Compass evening TV news program.

A Charlottetown biotech company has joined the fight against COVID-19 by creating antibodies that could help detect the presence of the virus in humans.

The COVID-19 virus has spike proteins on it. Those spikes are used by the virus to attach to human cells.

A company in China created a synthetic replica of those spike proteins in early February. Jon Zuccolo, founder and CEO of AffinityImmuno, reached out to that company and asked for the synthetic protein.

“The protein itself is fully synthetic.… It’s not isolated from the virus itself,” he said.”I requested some for testing thinking that it would be a potentially interesting project in the future, not realizing that it was going to become sort of all-encompassing for many companies around the globe.”

‘Pretty non-invasive’

​​Zuccolo began putting those synthetic spikes into chickens. As the chickens react to them, they create antibodies to fight them. Then, Zuccolo collects eggs from the chicken and takes the antibodies out of them.

“It’s a pretty non-invasive, hands-off approach to making antibodies very quickly,” he said.

Zuccolo compared the results from his chickens with other companies from around the world to make sure that his antibodies matched ones created by the actual virus.

“I tested these antibodies in early March and found that the hens actually did produce a very strong antibody response against a synthetic viral protein,” he said.

And then as the COVID-19 situation progressed globally, there was a big push for research into the virus, said Zuccolo.”I found myself kind of at the centre of attention from really hundreds of companies around the globe looking to test my antibodies in their different applications,” he said.

Antibodies react to COVID-19

Zuccolo is giving those antibodies to an international group of companies that is working on developing a rapid test for COVID-19.

“These are chicken proteins that will stick very efficiently to the virus or viral proteins,” said Zuccolo. “As such they can be used as a sort of probe in generating what’s called a rapid test, or point-of-care test.”

Zuccolo said it could produce a result in about five to 10 minutes.

“So this would be a testing methodology that you could do sort of on-site very quickly.”

Similar to the current COVID-19 test, this would also involve taking a sample from the back of a person’s throat and putting it into a test that resembles a pregnancy test. Those chicken antibodies react with the COVID-19 virus in that fluid, said Zuccolo.

“As it stands now one line would indicate that it’s negative for coronavirus or COVID-19 and two lines would indicate that it’s positive,” he said.

He said before it arrives on the market, it needs to be approved by Health Canada.

Test for past exposure

He said he’s also starting to think about applying the technology to a test for those who may have been exposed to COVID-19, and not know it.

Because those chicken antibodies are similar to the ones that are created by a human to fight COVID-19, Zuccolo said he can use them to determine if someone had ever been exposed to the virus.

If they hadn’t been exposed, they wouldn’t have those antibodies present.

“So it’s really just to test whether a person has come in contact with the COVID-19 virus in the past,” he said.Now, Zuccolo has started to expand his operation, adding more hens to his flock to supply the consortium with more antibodies as well as hiring more employees.”It’s exciting, actually really exciting. I’ve got a lot of support from scientists that I know and work with, as well as just people that just reached out and said, ‘You know, anything you want to work on let me know,'” he said.”I’m very happy to be part of it.”

Posted in Clients, COVID-19 News

Emergence Companies respond to the COVID-19 challenge

As essential service staff work long hours and families distance themselves from others by hunkering down in their homes, bioscience companies and their employees are flexing their research, development and manufacturing muscle to help in the fight against COVID-19.

Seven Emergence companies are developing products to strengthen human resistance to diseases, hand sanitizer, technologies to test if someone is or has been infected by COVID-19, and technologies to give specialists an online view for remote diagnoses.

AffinityImmuno in Charlottetown is part of an international consortium currently testing a rapid diagnostic test to screen for the virus in bodily fluids. Additionally, AffinityImmuno is developing a lab test to identify biomarkers that indicate protection against infection or reinfection by COVID-19.

BioSpa – Quannessence Skincare has created QuannShield, a pocket-sized hand sanitizer that’s a Health Canada-compliant sanitizing spray. Recognizing that hand sanitizers can lead to dry hands, Quannessence has included in its formulation, skin-hydrating characteristics making the product unique compared to other sanitizers. Their products are available in Murphy’s Pharmacies across PEI, and from the soon-to-be online store http://www.shopquannessence.com.

Avivagen is better known for its animal health technologies, such as its OxC Beta supplement that boosts immunity and reduces inflammation in livestock and companion animals, minimizing the need for antibiotic use. Now, Avivagen is evaluating OxC Beta’s potential to boost the human immune system and help people afflicted by respiratory problems from lung inflammation due to COVID-19 or other illnesses.

Fieldetect Inc, co-founded by UPEI professors, recently received $355K from the Canadian Institutes for Health Research (CIHR) to modify its handheld LabAnywhere technology for the COVID-19 cause. Initially designed to quickly detect viruses in animals, the Fieldetect technology shows promise for testing viruses like COVID-19 in humans.

Somru BioScience is drawing on its antibody platform technology to assist in developing therapeutic and diagnostic solutions for COVID-19 and other infectious diseases. Their experience in immunoassay development will enable them to provide diagnostic and research solutions for future infectious disease outbreaks. Somru’s plans include shortening the development time of diagnostic kits for future infectious diseases by 50 percent.

TerraVerdae Bioworks in is leveraging its core capabilities in functional biomaterials and bioactives to develop enhanced antiviral protection products for front line workers working in infectious disease response.

VetNOW‘s telemedicine technology has received new prominence under pandemic conditions, allowing local veterinarians to reach veterinary specialists at a distance through their online platform, providing improved care for food animals and companion animals. A new partnership with Elanco Animal Health has made the VetNOW’s technology available for free for two months for veterinarians who enroll in Canada and the United States.

We can be proud of the collective efforts of the Emergency community in helping Canadians get through the current COVID-19 situation and better preparing us to prevent and respond to future infectious disease outbreaks.

Posted in Clients, News

CATC acquires research facility

Emergence client Center for Aquaculture Technologies (CAT) has finalized a deal with Elanco Animal Health Incorporated to acquire a 46,000 square foot aquatic animal research facility in Victoria, Prince Edward Island. The acquisition, which includes expansive, purpose-built, wet and dry lab space, is an exciting step as CAT grows its reputation as a globally recognized Health and Nutrition Contract Research Organization. The addition of the Victoria facility will triple the company’s Canadian footprint and expand the already best-in-class research services in Health and Nutrition, allowing the company to double the number of research trials conducted on an annual basis.

CAT Chief Executive Officer, Dr. John Buchanan confirmed that the transaction with Elanco was closed earlier today. “We are experiencing exciting growth in our aquaculture Health and Nutrition Research Services business and have immediate plans for use of the facility.” said Buchanan, “Expanding our footprint will allow our team to meet the demands of the global aquaculture community on a larger scale. We are thrilled to have the opportunity to expand our offerings and add to our world-class team.”

Adding to the extensive experience of the existing Canadian team, Dr. Jason Cleaversmith has been hired as Vice President of Health and Nutrition and General Manager of Canadian Operations. He brings more than 17 years of experience in aquaculture management and will oversee operations at the new facility .”The Victoria site has a long history of setting the gold standard for pivotal regulatory trials and innovation, and CAT is fortunate to have been able to acquire this state- of- the- art facility, along with several staff who are well versed in operating in a quality centric, highly regulated environment. This is a timely and exciting addition to the CAT facility network” said Cleaversmith.

With the addition of the new facility, the only other privately held Aquatic Animal Pathogen Containment level 3 (AQC3/BSL3) certified lab space in Canada, CAT will oversee the largest amount of AQC3 certified square footage in the world, enabling the company to scale its research activities involving domestic and imported aquatic animals, and aquatic animal pathogens. The Victoria site will operate in addition to the CAT Research Aquarium and Labs in Souris, PEI and San Diego, California. The Government of Prince Edward Island will support the project with a repayable loan of $4 million from the PEI Century Fund. “The Center for Aquaculture Technologies provides vital research and development for the aquaculture industry in our province,” said Minister of Economic Growth, Tourism and Culture Matthew MacKay. “We are proud to support CAT’s expansion, that will keep jobs in the community.”

The CAT team specializes in collaborative and contract research services, working with clients worldwide to develop customized solutions to improve productivity, efficiency, and sustainability in the
aquaculture industry. In addition to expertise in Fish Health and Nutrition, CAT’s skilled team of researchers in Canada, and the US, offer specialized and custom services in the fields of Genotyping, Diagnostics, Breeding, Genomics, and Molecular Biology.

The Center for Aquaculture Technologies is an R&D and contract service organization focused on the application of biotechnologies to improve productivity, efficiency, and sustainability in aquaculture and related industries. The company combines extensive experience in aquaculture with a strong background in cellular and molecular technologies to provide research-based solutions. Find us at www.aquatechcenter.com

Posted in Uncategorized